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Introduction
 In the RCT on the prevention VTE events in 
hospitalized medical patients, prophylactic low-
molecular weight heparin (LMWH) > 
unfractionated heparin (UFH) 
 Similar high-impact trials have validated more 
favorable results with prophylactic LMWH over 
UFH in general surgery, trauma surgery, 
orthopaedic surgery, urology, and 
cardiopulmonary specialties.
Methods
 In 2017, the Accreditation Council for Graduate 
Medical Education (AGME) provided the contact 
information for the program coordinators of all 
107 ACGME-approved neurosurgery residency 
programs
 Electronic survey on three pathologies: (1) 
degenerative/ deformity, (2) trauma, (3) neoplasm
Respondents: 69 Residency Programs
Results
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Evidence-Based Clinical Guidelines
 Level IV evidence that has supported 
chemoprophylaxis on the day of spinal surgery
 Administering an anticoagulant, albeit a very 
small dose, prior to the procedure portends a 
higher risk of bleeding complications. 
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Discussion
 NASS Evidence-Based Clinical Guidelines 
specified LMWH as a chemoprophylactic drug of 
choice without mention of UFH 
 But, for therapeutic doses of anticoagulation, 
guidelines take preference to intravenous UFH 
because LMWH is less “predictable.” 
Neoplasms
 In a prospective double-blind randomized multicenter 
trial after elective cancer surgery, the ENOXACAN Study 
found that the thromboembolic complication rate of 
18.2% in the heparin group did not statistically 
significantly differ from 14.7% in the enoxaparin group 
 The NASS Evidence-Based Clinical Guidelines 
determined that “Evidence [for chemoprophylaxis] is 
better established in higher risk patients undergoing 
spinal surgery for traumatic or neoplastic conditions
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